Literature DB >> 15882288

Rapamycin inhibits human renal epithelial cell proliferation: effect on cyclin D3 mRNA expression and stability.

Nicolas Pallet1, Eric Thervet, Delphine Le Corre, Bertrand Knebelmann, Patrick Nusbaum, Céline Tomkiewicz, Paul Meria, Jean-Pierre Flinois, Philippe Beaune, Christophe Legendre, Dany Anglicheau.   

Abstract

BACKGROUND: Recent data have suggested that rapamycin use during the initial period after transplantation is associated with prolonged delayed graft function (DGF). Because of the known effects of rapamycin in other cell types, we speculated that this action may be secondary to human renal epithelial cells (HRECs) inhibition of proliferation.
METHODS: Primary cultures of HRECs were incubated with various concentrations of rapamycin. Cell proliferation was evaluated by cytotoxicity assays. The cell cycle was analyzed by flow cytometry. Protein expression levels were assessed by Western blot. Cyclin D3 mRNA levels were measured by quantitative real-time polymerase chain reaction (PCR). The transcriptional activity of the cyclin D3 gene was evaluated using transient transfection.
RESULTS: Rapamycin exerted a significant concentration-dependent antiproliferative effect on growing HRECs by inhibiting the G(1) to S transition. The p70(S6) kinase pathway leading to cell cycle progression was found to be active, and low concentrations of rapamycin dramatically reduced p70(S6) kinase phosphorylation. Rapamycin completely inhibited the increase in cyclin D3 protein expression and mRNA accumulation induced by fetal calf serum, but did not affect cyclin E or cdk-inhibitor expression levels. This regulation of cyclin D3 protein expression is mainly due to a destabilization of its mRNA. Rapamycin reduced the mRNA half-life by 26% (4.8 +/- 1.3 hours vs. 6.5 +/- 1.0 hours, P < 0.001).
CONCLUSION: Rapamycin inhibits the proliferative response of HRECs to mitogenic stimuli, and causes cell cycle arrest in the early G(1) phase, not only by a nonspecific process due to inhibition of the p70(S6k) pathway, but also by a direct effect on cyclin D3 mRNA stability.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882288     DOI: 10.1111/j.1523-1755.2005.00350.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  18 in total

1.  The unfolded protein response regulates an angiogenic response by the kidney epithelium during ischemic stress.

Authors:  Nicolas Bouvier; Sophie Fougeray; Philippe Beaune; Eric Thervet; Nicolas Pallet
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

2.  High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria.

Authors:  Nicolas Pallet; Iadh Mami; Caroline Schmitt; Zoubida Karim; Arnaud François; Marion Rabant; Dominique Nochy; Laurent Gouya; Jean-Charles Deybach; Yichum Xu-Dubois; Eric Thervet; Hervé Puy; Alexandre Karras
Journal:  Kidney Int       Date:  2015-04-01       Impact factor: 10.612

3.  Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and Mammalian target of rapamycin.

Authors:  Liliana Schaefer; Wasiliki Tsalastra; Andrea Babelova; Martina Baliova; Jens Minnerup; Lydia Sorokin; Hermann-Josef Gröne; Dieter P Reinhardt; Josef Pfeilschifter; Renato V Iozzo; Roland M Schaefer
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

4.  Therapeutics in renal disease: the road ahead for antiproliferative targets.

Authors:  Peter J Nelson; Stuart J Shankland
Journal:  Nephron Exp Nephrol       Date:  2005-12-07

Review 5.  Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review.

Authors:  Ernesto Paoletti; Franco Citterio; Alberto Corsini; Luciano Potena; Paolo Rigotti; Silvio Sandrini; Elisabetta Bussalino; Giovanni Stallone
Journal:  J Nephrol       Date:  2019-04-27       Impact factor: 3.902

6.  The physiology and pathophysiology of rapamycin resistance: implications for cancer.

Authors:  Philip A Gruppuso; Joan M Boylan; Jennifer A Sanders
Journal:  Cell Cycle       Date:  2011-04-01       Impact factor: 4.534

7.  Angiogenin Mediates Cell-Autonomous Translational Control under Endoplasmic Reticulum Stress and Attenuates Kidney Injury.

Authors:  Iadh Mami; Nicolas Bouvier; Khalil El Karoui; Morgan Gallazzini; Marion Rabant; Pierre Laurent-Puig; Shuping Li; Pierre-Louis Tharaux; Philippe Beaune; Eric Thervet; Eric Chevet; Guo-Fu Hu; Nicolas Pallet
Journal:  J Am Soc Nephrol       Date:  2015-07-20       Impact factor: 10.121

8.  CRISPR/Cas9-Engineered HLA-Deleted Glomerular Endothelial Cells as a Tool to Predict Pathogenic Non-HLA Antibodies in Kidney Transplant Recipients.

Authors:  Baptiste Lamarthée; Carole Burger; Charlotte Leclaire; Emilie Lebraud; Aniela Zablocki; Lise Morin; Xavier Lebreton; Béatrice Charreau; Renaud Snanoudj; Soëli Charbonnier; Tifanie Blein; Mélanie Hardy; Julien Zuber; Simon Satchell; Morgan Gallazzini; Fabiola Terzi; Christophe Legendre; Jean Luc Taupin; Marion Rabant; Claire Tinel; Dany Anglicheau
Journal:  J Am Soc Nephrol       Date:  2021-12       Impact factor: 10.121

9.  MicroRNA-146a in Human and Experimental Ischemic AKI: CXCL8-Dependent Mechanism of Action.

Authors:  Lucile Amrouche; Geoffroy Desbuissons; Marion Rabant; Virginia Sauvaget; Clément Nguyen; Aurélien Benon; Pauline Barre; Clémentine Rabaté; Xavier Lebreton; Morgan Gallazzini; Christophe Legendre; Fabiola Terzi; Dany Anglicheau
Journal:  J Am Soc Nephrol       Date:  2016-07-21       Impact factor: 10.121

10.  Met activation is required for early cytoprotection after ischemic kidney injury.

Authors:  Sherene Mason; Carlos Hader; Arnaud Marlier; Gilbert Moeckel; Lloyd G Cantley
Journal:  J Am Soc Nephrol       Date:  2013-10-17       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.